Megan Kruse, MD

Despite being the second most prevalent histologic subtype of invasive breast cancer in the U.S., invasive lobular carcinoma is often detected later and yields worse outcomes than invasive ductal carcinoma, the most common invasive subtype.

In this video, Megan Kruse, MD, a medical oncologist at Cleveland Clinic, spoke with Healio about findings from the IPATunity130 trial.

At the virtual San Antonio Breast Cancer Symposium, researchers presented results from the monarchE and PENELOPE-B trials that investigated ways to “improve cure rates and decrease recurrence rates among women with high-risk breast cancer.”